Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Thyroid Cancer Drugs Industry By 2029?

In recent times, the market size for drugs related to thyroid cancer has seen significant growth. The growth projection forecasts an increase from $1.16 billion in 2024 to $1.32 billion in 2025, marking a compound annual growth rate (CAGR) of 13.6%. This growth experienced in the past can be credited to factors such as the increase in thyroid cancer cases, progress in medical research, supportive regulatory conditions, and an upward trend in healthcare spending.

The market for thyroid cancer drugs is projected to experience swift augmentation in the coming years, expanding to “$2.12 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 12.6%. This growth during the predicted period can be credited to factors such as the increasing incidences and an aging demographic, advancements in precision medicine, the evolution of healthcare infrastructure, boosted awareness, and early diagnosis. Notable trends during this forecast period encompass personalized medicine, specific therapies, and immunotherapies, along with clinical trials and drug pipeline, amalgamation therapies, treatments driven by biomarkers, telemedicine, and distant monitoring.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp

What Are The Primary Factors Supporting The Thyroid Cancer Drugs Market Expansion?

The thyroid cancer medication market is experiencing growth due to the upsurge in cases of thyroid cancer, predominantly in women. Data from The American Cancer Society, an organization based in the US, estimated approximately 43,800 new thyroid cancer cases in 2022 in the United States alone. These included 31,940 cases in women and 11,860 cases in men. There were also 2,230 fatalities due to thyroid cancer, which consisted of 1,070 men and 1,160 women. As such, the escalating rate of thyroid cancer, particularly in women, is propelling the expansion of the thyroid cancer market.

How Is The Global Thyroid Cancer Drugs Market Broken Down By Segment?

The thyroid cancer drugs market covered in this report is segmented –

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users

Subsegments:

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib

8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab

Which Trends Are Likely To Redefine Growth Paths In The Thyroid Cancer Drugs Market?

The use of combination drugs in the management of thyroid cancer is on the rise, given their superior efficacy and ability to curb cancer progression. A combination drug is one that integrates two or more active pharmaceutical ingredients (APIs) into one dosage form. These medications have the benefit of slowing down drug resistance development and inhibiting cancer cell proliferation. For example, the FDA has sanctioned the combined use of dabrafenib (Tafinlar), a BRAF inhibitor, with trametinib (Mekinist), a MEK inhibitor, for the treatment of anaplastic thyroid cancer.

Who Are The Most Influential Companies In The Thyroid Cancer Drugs Market?

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Thyroid Cancer Drugs Market?

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2601&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model